Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03170544 · ClinicalTrials.gov registry record · Phase 1
Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 69
- Enrollment target
NCT03170544 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 69 participants.
The verdict
NCT03170544, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 69 participants
- Enrollment target
Study Summary
This is an active- and placebo-controlled, single-site, four-part trial of MK-1092 in healthy adult participants, in participants with type 1 diabetes mellitus (T1DM), and in participants with type 2 diabetes mellitus (T2DM). The primary hypothesis for this study is that at a dose with sufficient safety, the mean maximal glucose infusion rate (GIRmax) after single subcutaneous (SC) administration of MK-1092 in adult participants with T1DM is within an acceptable range. (Part 3)
Interventions
- DRUG MK-1092, 4.0 nmol/kg
- DRUG MK-1092, 8.0 nmol/kg
- DRUG MK-1092, 16 nmol/kg
- DRUG MK-1092, 32 nmol/kg
- DRUG MK-1092, 64 nmol/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2017-08-16 |
| Est. Completion | 2018-11-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03170544
The ClinicalTrials.gov registry entry for NCT03170544 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which MK-1092, 4.0 nmol/kg is the first listed.
NCT03170544 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03170544 about?
NCT03170544 is a clinical study titled "Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001)". This is an active- and placebo-controlled, single-site, four-part trial of MK-1092 in healthy adult participants, in participants with type 1 diabetes mellitus (T1DM), and in participants with type 2 diabetes mellitus (T2DM). The primary hypothesis for this study is that at a dose with sufficient sa...
What is the current status of trial NCT03170544?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 69 participants. The study started on 2017-08-16. Estimated completion is 2018-11-08.
What interventions are being tested in trial NCT03170544?
The interventions under investigation include: MK-1092, 4.0 nmol/kg (DRUG), MK-1092, 8.0 nmol/kg (DRUG), MK-1092, 16 nmol/kg (DRUG), MK-1092, 32 nmol/kg (DRUG), MK-1092, 64 nmol/kg (DRUG).
Who is sponsoring clinical trial NCT03170544?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.